Raxibacumab Approved for Inhalational Anthrax

Neutralizes anthrax toxins, which can kill

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Dec. 14, 2012 (HealthDay News) -- Raxibacumab injection has been approved by the U.S. Food and Drug Administration to treat inhalational anthrax, an infectious disease caused by breathing in deadly anthrax spores, the agency said Friday.

Raxibacumab neutralizes the toxins produced by the anthrax bacterium Bacillus anthracis. This infection can cause "massive and irreversible tissue injury and death," the FDA said in a news release.

Raxibacumab is a monoclonal antibody, acting like a human antibody that attacks foreign bacteria and viruses.

Anthrax, the FDA said, "is a potential biological terrorism threat because the spores are resistant to destruction and can be easily spread by release in the air."

"In addition to antibiotics, raxibacumab will be a useful treatment to have available should an anthrax bioterrorism event occur," Dr. Edward Cox, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research, said in the news release. "Although antibiotics are approved to prevent and treat anthrax infection, raxibacumab is the first approved agent that acts by neutralizing the toxins produced by B. anthracis."

Raxibacumab's effectiveness was evaluated in monkeys and rabbits. Between 44 percent and 64 percent of the animals survived exposure to anthrax after being treated with raxibacumab, compared to none that survived anthrax exposure in an untreated control group.

Raxibacumab was developed by Human Genome Sciences, based in Rockville, Md.

More information

To learn more about anthrax exposure, visit the U.S. Centers for Disease Control and Prevention.


Last Updated: